Short Interest in Actinium Pharmaceuticals Inc (ATNM) Rises By 8.0%
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,722,835 shares, a growth of 8.0% from the January 12th total of 1,594,647 shares. Approximately 2.3% of the company’s shares are sold short. Based on an average trading volume of 605,591 shares, the days-to-cover ratio is presently 2.8 days.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) opened at $0.60 on Wednesday. Actinium Pharmaceuticals has a one year low of $0.53 and a one year high of $1.68. The firm has a market cap of $43.19, a P/E ratio of -1.28 and a beta of 40.77.
A number of research analysts have weighed in on ATNM shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. Roth Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, Maxim Group set a $3.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 30th. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $3.75.
ILLEGAL ACTIVITY NOTICE: “Short Interest in Actinium Pharmaceuticals Inc (ATNM) Rises By 8.0%” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/14/short-interest-in-actinium-pharmaceuticals-inc-atnm-rises-by-8-0.html.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.